AstraZeneca will 2023 Year 9 Month 9 Date 13 Day in Milan, Italy 2023 European Respiratory Society(ERS)AstraZeneca to Present Latest Real-World Clinical Research Data on Its Leading Inhalers, Biologics, and Early Respiratory Portfolio at International Conference 93 Abstract, which includes 18 Oral presentation at the venue, focusing on severe asthma and chronic obstructive pulmonary disease (COPD)And other unmet needs in acute respiratory diseases.
Executive Vice President, Global Head of BioPharmaceuticals, AstraZenecaRuud Dobber Indicates:“Unlike many other immune-mediated diseases,‘Alleviate’Not an established goal of asthma treatment.ERSThe key data displayed above showcasesFasenra(Common name:benralizumab) andTezspire(Common name:tezepelumab) The huge potential in alleviating asthma, improving medical standards, and further enhancing patients' lives. Based on these data, we can see the significant progress AstraZeneca has made in improving the treatment of asthma, chronic obstructive pulmonary disease, and other respiratory diseases.”
benralizumabIt is a monoclonal antibody that directly binds to eosinophils onIL-5RαCombine, and AttractNKCells, leading to almost complete depletion of eosinophils through apoptosis (programmed cell death), with the depletion process being rapid.。benralizumabIt is AstraZeneca's first biologic for respiratory conditions, currently approved in the United States, the European Union, Japan, and several other regions as an add-on maintenance treatment for severe eosinophilic asthma. Based onMIRACLE III The excellent results of the Phase trial, the National Medical Products Administration of China (NMPA) Official AcceptancebenralizumabApplication for the Market Launch of a New Drug to Treat Severe Asthma
Clinical remission is a higher treatment goal for severe asthma, typically including: no acute exacerbations; not receiving oral corticosteroids.(OCS)Maintenance treatment; Stable lung function; Long-term absence of significant asthma symptoms。
Multiple clinical studies have shown that biologicsbenralizumabFor the treatment of severe eosinophilic asthma(SEA)Leading Therapies in Biologics
- SHAMAL IV Phase Trial:This breakthrough clinical trial is the first to report that biologics can significantly reduce background medication (inhaled corticosteroids) in patients with severe asthma.ICS) Dose。
- BORA III Extended Trial Period andXALOC(RWE)Project:These two studiesSEAThe patient received more than2Year'sbenralizumabTreatment: Research results provide evidence supporting clinical remission as an achievable and sustainable treatment goal.。
- MIRACLE III Phase Trial:The latest data from this study evaluatedbenralizumabUncontrolled disease in China and other Asian countries SEA Efficacy and Safety in Patients. The findings of the study indicate that,benralizumabAfter treatment, the acute exacerbation rate of severe asthma patients was significantly reduced both clinically and statistically.。
Multiple clinical studies have shown,tezepelumabMay provide sustained relief for a broad population of patients with severe asthma
- DESTINATION III Post-hoc exploratory analysis showed,Compared with placebo, in a broad population of severe asthma patients without phenotypic or biomarker restrictions,tezepelumabCan bring more than2Years of sustained clinical remission。
- After the treatment endsDESTINATION III The extended study analysis shows,tezepelumabThe therapeutic effect decreased after discontinuation of the drug. However, after the last dose9Within months, the patient's biomarker levels and clinical outcomes remained better than the baseline. This result indicates the long-term usetezepelumabImportance。
Emphasizing the Urgency of Preventing COPD Exacerbations Through New Real-World Data on Cardiopulmonary Risks
- EXACOS-CV Multinational Retrospective Cohort Study:From more than30The latest real-world data from ten thousand patients with chronic obstructive pulmonary disease (COPD) shows that patients who have experienced acute exacerbations in the past...6The risk of serious cardiovascular events increases within months, and this risk remains high within a year.. These data highlight the importance of preventionCOPDThe Importance of Acute Exacerbation in Reducing Cardiopulmonary Risk and Mortality。
Scientific Progress in the Early Pipeline
- Cytokines, Interleukins 33 (IL-33) Research:FromACCORD-2 IIa The latest efficacy and safety data from the phase trial confirmed that tozorakimab (a IL-33 Neutralizing monoclonal antibodies can serve as a potential treatment option for patients hospitalized due to COVID-19.。
- Will share exploratory research findings to showcase new platform research IL-33 The Potential of Biology and Screening for Novel Therapies。
- Research on Early Chronic Obstructive Pulmonary Disease:New Approaches to Identify Biomarkers for Early Chronic Obstructive Pulmonary Disease to Improve Early Diagnosis。
References:
1，Menzies-Gow A, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757-765.
2，AstraZeneca plc. H1 and Q2 2023 Results Presentation. Available at: https://www.astrazeneca.com/content/dam/az/PDF/2023/h1/H1-and-Q2-2023-results-announcement.pdf. [Last accessed: August 2023].
3，Jackson D, et al. SHAMAL: Reduction of Maintenance Inhaled Corticosteroids in Patients with Severe Eosinophilic Asthma Treated with Benralizumab: A Randomised Phase 4 Study. [Oral Presentation]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
4，Lommatzsch, M, et al. Durability of Benralizumab-induced remission in severe asthma: an analysis of the BORA study [Oral Presentation]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
5，Pelaia, G, et al. Patients with severe eosinophilic asthma achieved remission over 2 years with benralizumab: Integrated analysis of the >1000-patient, multinational, real-world XALOC-1 study [Poster Session]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
6，Lai, K, et al. Efficacy and safety of benralizumab in patients with severe uncontrolled asthma despite ICS-LABA: a randomised, double-blind, placebo-controlled phase 3 trial in Asia (MIRACLE) [Poster Session]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
7，Huang K, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019; 394: 407-418.
8，AstraZeneca plc. H1 and Q2 2023 Results Clinical Trials Appendix. Available at: https://www.astrazeneca.com/content/dam/az/PDF/2023/h1/H1-and-Q2-2023-results-clinical-trials-appendix.pdf. [Last accessed: August 2023].
9，Wechsler, ME, et al. On-treatment clinical remission with tezepelumab in patients with severe, uncontrolled asthma in the phase 3 DESTINATION study [Poster Session]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
10，Brightling, C, et al. Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (DESTINATION) [Oral Presentation]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
11，Vogelmeier, C, et al. Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study [Poster Session]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
12，GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2023. [Online]. Available at: http://goldcopd.org. [Last accessed: August 2023]
13，Wilkinson, T, et al. Tozorakimab in patients hospitalised with COVID-19: a phase 2, randomised adaptive platform study (ACCORD-2) [Poster Session]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
14，England E, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023 Jun 17;13(1):9825.
15，Stephenson, K, et al. Development of a huPCLS platform to explore IL-33 biology and test novel therapies [Poster Session]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
16，Ritchie, AI, et al. Characterising radiological abnormalities in Early COPD [Poster Session]. Presented at the European Respiratory Society (ERS) International Congress 2023 (9-13 September).
17，Chung, KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73.
18，The Global Asthma Network. The Global Asthma Report 2022. Available at: http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf. [Last accessed: August 2023.]
19，Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005;172:149-60.
20，Fernandes AG, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol. 2014; 40: 364-372.
21，Peters SP, et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100(7):1139-51.
22，World Health Organization. The Top 10 Causes of Death. Accessible at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. [Last accessed: August 2023].
23，Adeloye D, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. (2022) Vol 10(5); 447-458.
24，AstraZeneca. Fasenra Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf. [Last accessed: August 2023].
25，Corren J, et al. Tezepelumab in adults with uncontrolled asthma [supplementary appendix; updated April 18, 2019]. N Engl J Med. 2017;377:936-946.
26，Varricchi G, et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front Immunol. 2018;9:1595.
27，AstraZeneca plc. Tezspire (tezepelumab) approved in the US for severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma.html. [Last accessed: August 2023].
28，AstraZeneca plc. Tezspire approved in the EU for the treatment of severe asthma. 2022. Available at: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/tezspire-approved-in-the-eu-for-the-treatment-of-severe-asthma.html. [Last accessed: August 2023].
29，AstraZeneca plc. Tezspire approved in Japan for the treatment of severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html. [Last accessed: August 2023].